Loading patent…
AssigneeJapanese Foundation for Cancer Research
InventorsToru Hirota, Motoko Takahashi, Minji Jo, Utako Kato, Nana Kamakura, Norika Kawakita
Estimating the term…
It was found that enhancement of Plk1 activity induces lethal abnormalities in chromosome dynamics in cancer cells, causing the growth to be suppressed. Therefore, activating Plk1 and exacerbating chromosome instability can lead to lethal abnormalities in chromosome dynamics and suppress the growth of cancer cells. Provided are a method for screening a medicine and a pharmaceutical composition based on a new drug discovery concept in which activating a kinase that exhibits enhanced expression in cancer cells causes the suppression of cancer cell growth.
A method for screening a medicine that targets polo-like kinase 1 (Plk1), in which Plk1 activation by addition of a candidate compound is used as an indicator.
A method for suppressing cancer cell growth, in which the growth is suppressed by activating Plk1.
A pharmaceutical composition for treating cancer, in which a compound that activates Plk1 is used as an active ingredient.
Dependencies are inferred from the claim text.